Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Transcriptional Differences Between Males and Females in Childhood Group 4 Medulloblastoma

FY 2018-19

Summary
Medulloblastoma (MB) is the most common childhood brain tumour and can be divided into four subgroups based on distinct clinical and molecular characteristics: Wingless, Sonic Hedgehog, Group 3 and Group 4. Group 4 MB is the most commonly diagnosed subgroup (35% of all MB cases) and cases are three times higher in boys than in girls. Furthermore, boys tend to have worse outcomes following standardized treatments than girls. While the higher incidence among males has been well documented, the biological underpinnings of these differences remain unknown. Due to the early age of onset and male bias in incidence, we suspect that there are inherent differences in gene expression by specific cell types during the development of the cerebellum, where these tumours are often diagnosed. Furthermore, we hypothesize that differences in these expressed genes predispose males to developing Group 4 MB. To investigate our hypothesis, we will compare gene expression in developing male and female mouse embryonic hindbrain using a powerful, new technique called single cell RNA sequencing. This gene expression will be matched to tumour gene expression profiles from male and female patients to identify genes that predispose males to developing Group 4 MB. Our research will bring us closer to understanding why Group 4 MB is more prevalent in males than in females, and what predisposes males to developing these tumors. Furthermore, this information will allow us to improve the standardized therapies and clinical outcomes of male patients diagnosed with these aggressive, childhood malignancies.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406522
Name
Ong Winnie
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Transcriptional Differences Between Males and Females in Childhood Group 4 Medulloblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Genetic Predisposition; Group 4 Medulloblastoma; Male; Medulloblastoma; Mouse; Neoplasm; Pediatrics; Sex Characteristics; Single Cell Rna Sequencing; Transcriptome
Abstract
Medulloblastoma (MB) is the most common childhood brain tumour and can be divided into four subgroups based on distinct clinical and molecular characteristics: Wingless, Sonic Hedgehog, Group 3 and Group 4. Group 4 MB is the most commonly diagnosed subgroup (35% of all MB cases) and cases are three times higher in boys than in girls. Furthermore, boys tend to have worse outcomes following standardized treatments than girls. While the higher incidence among males has been well documented, the biological underpinnings of these differences remain unknown. Due to the early age of onset and male bias in incidence, we suspect that there are inherent differences in gene expression by specific cell types during the development of the cerebellum, where these tumours are often diagnosed. Furthermore, we hypothesize that differences in these expressed genes predispose males to developing Group 4 MB. To investigate our hypothesis, we will compare gene expression in developing male and female mouse embryonic hindbrain using a powerful, new technique called single cell RNA sequencing. This gene expression will be matched to tumour gene expression profiles from male and female patients to identify genes that predispose males to developing Group 4 MB. Our research will bring us closer to understanding why Group 4 MB is more prevalent in males than in females, and what predisposes males to developing these tumors. Furthermore, this information will allow us to improve the standardized therapies and clinical outcomes of male patients diagnosed with these aggressive, childhood malignancies.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ong, Winnie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~